Efficacy and Safety of Anti–B-Cell Maturation Antigen Chimeric Antigen Receptor T-Cell for the Treatment of Relapsed and Refractory AL Amyloidosis

This largest clinical trial of AL patients treated with anti-BCMA CART demonstrates acceptable and manageable toxicity in a highly frail and resistant population with remarkable efficacy, leading to fast organ responses. Among patients with baseline advanced cardiac disease, deaths in the first year were frequent, suggesting that this effective therapy should be considered earlier in the course of therapy. Anti-BCMA CART may become a powerful tool for improving organ function and survival in patients with AL.

Authors

Institutions

Publication Details

Journal
Journal of Clinical Oncology
Published
2024-12-10
DOI
https://doi.org/10.1200/jco-24-02252
Citations
17
Primary Topic
Amyloidosis: Diagnosis, Treatment, Outcomes
Type
article
Field-Weighted Citation Impact
3.97
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Efficacy and Safety of Anti–B-Cell Maturation Antigen Chimeric Antigen Receptor T-Cell for the Treatment of Relapsed and Refractory AL Amyloidosis

Nathalie Asherie, Moshe E. Gatt, Sigal Grisariu, Polina Stepensky et al.
17 citations
Journal of Clinical Oncology
Amyloidosis: Diagnosis, Treatment, Outcomes
3.97
article

Efficacy and Safety of Anti–B-Cell Maturation Antigen Chimeric Antigen Receptor T-Cell for the Treatment of Relapsed and Refractory AL Amyloidosis

Nathalie Asherie, Moshe E. Gatt, Sigal Grisariu, Polina Stepensky, Shlomit Kfir‐Erenfeld, Batia Avni, Alaa Shehadeh, Eyal Lebel, Shlomo Elias, Rivka Alexander‐Shani, Miri Assayag, Vladimir Vainstein, Eran Zimran, Yael Chava Cohen, Irit Avivi, Cyrille J. Cohen, Marjorie Pick, Aseel Ishtay, Nomi Bessig, Tali Dubnikov-Sharon, Shelly Pimienta, Shlomit Herr
article en
17 citations

Abstract

This largest clinical trial of AL patients treated with anti-BCMA CART demonstrates acceptable and manageable toxicity in a highly frail and resistant population with remarkable efficacy, leading to fast organ responses. Among patients with baseline advanced cardiac disease, deaths in the first year were frequent, suggesting that this effective therapy should be considered earlier in the course of therapy. Anti-BCMA CART may become a powerful tool for improving organ function and survival in patients with AL.

Journal of Clinical OncologyVol. 43(17)
Bar-Ilan University (IL), Tel Aviv University (IL), Hebrew University of Jerusalem (IL), Hadassah Medical Center (IL)
Good health and well-being
Openalex Percentile: Top 5%
Amyloidosis: Diagnosis, Treatment, Outcomes
3.97
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.